Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.
Fiche publication
Date publication
février 2019
Journal
Health and quality of life outcomes
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PAGET-BAILLY Sophie, Mme POZET Astrid, Dr THIERY-VUILLEMIN Antoine, Dr MOUILLET Guillaume, Dr VERNEREY Dewi
Tous les auteurs :
Mouillet G, Fritzsch J, Paget-Bailly S, Pozet A, Es-Saad I, Meurisse A, Vernerey D, Mouyabi K, Berthod D, Bonnetain F, Anota A, Thiery-Vuillemin A
Lien Pubmed
Résumé
Two main therapies, pazopanib and sunitinib, are used in the first-line setting for metastatic renal cell carcinoma (mRCC). These two tyrosine kinase inhibitors (TKI) are equally effective in terms of survival; however, they frequently induce adverse events. In this setting, Health-Related Quality of life (HRQoL) is a key element in the choice between these two treatments and the evaluation of treatment effectiveness. It could be of interest to evaluate HRQoL in daily clinical practice to aid adequate therapy choice and management. Currently, the development of information and communication technology may allow HRQoL monitoring in routine practice. The objective of the QUANARIE study is to evaluate the use of HRQoL assessment in daily clinical practice for patients with mRCC treated with TKI using electronic patient-reported outcomes (e-PRO). The present article describes the key elements of the study protocol.
Mots clés
Health-related quality of life, Patient-reported outcome,sunitinib,pazopanib, Renal cell carcinoma
Référence
Health Qual Life Outcomes. 2019 Feb 4;17(1):25